Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(24)00539-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preferences of people living with HIV for features of tuberculosis preventive treatment regimens in Uganda: a discrete choice experiment.
J Int AIDS Soc
December 2024
Center for Tuberculosis, University of California San Francisco, San Francisco, California, USA.
Introduction: Tuberculosis (TB) preventive treatment (TPT) is recommended for people living with HIV (PLHIV) in high TB burden settings. While 6 months of daily isoniazid remains widely used, shorter regimens are now available. However, little is known about preferences of PLHIV for key features of TPT regimens.
View Article and Find Full Text PDFUrine-Xpert Ultra for the diagnosis of tuberculosis in people living with HIV: a prospective, multicentre, diagnostic accuracy study.
Lancet Glob Health
December 2024
FIND, Geneva, Switzerland. Electronic address:
Background: Diagnostic delays for tuberculosis are common, with high resultant mortality. Urine-Xpert Ultra (Cepheid) could improve time to diagnosis of tuberculosis disease and rifampicin resistance. We previously reported on lot-to-lot variation of the Fujifilm SILVAMP TB LAM.
View Article and Find Full Text PDFThe accuracy of point-of-care C-Reactive Protein as a screening test for tuberculosis in children.
PLOS Glob Public Health
October 2024
Tuberculosis Department, Centre of Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
Systematic screening for TB in children, especially among those at high risk of TB, can promote early diagnosis and treatment of TB. The World Health Organization (WHO) recently recommended C-Reactive Protein as a TB screening tool in adults and adolescents living with HIV (PLHIV). Thus, we aimed to assess the performance of point-of-care (POC) CRP as a screening tool for TB in children.
View Article and Find Full Text PDFMapping the existing body of knowledge on new and repurposed TB vaccine implementation: A scoping review.
PLOS Glob Public Health
August 2024
KNCV Tuberculosis Foundation, The Hague, The Netherlands.
There is global consensus on the urgent need for a safe and effective TB vaccine for adults and adolescents to improve global TB control, and encouragingly, several promising candidates have advanced to late-stage trials. Significant gaps remain in understanding the critical factors that will facilitate the successful implementation of new and repurposed TB vaccines in low- and middle-income countries (LMICs), once available. By synthesizing the existing body of knowledge, this review offers comprehensive insights into the current state of research on implementation of these adult and adolescent vaccines.
View Article and Find Full Text PDFCROI 2024: Tuberculosis, Mpox, and Other Infectious Complications in People With HIV.
Top Antivir Med
July 2024
University of California San Francisco, San Francisco, California, USA.
Several novel antituberculosis agents, including long-acting injectable agents in mouse models, have shown promise in preclinical and early clinical studies. This encouraging news is offset by the failures of a tuberculosis (TB) vaccine to prevent disease recurrence and a 3-month clofazimine-based treatment regimen for drug-susceptible TB. Clinically focused insights regarding TB, mpox, and other HIV-associated infectious complications that were presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) are summarized in this review.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!